Post by
kuatolives on Aug 11, 2016 6:53pm
Zack's
Zacks as a new research report on ARLZ. Can't seem to link to it other than from my phone, but long story short they're putting $10 on the shares (plus or minus) with another tidbit that most of the offers to their 110 drug reps are contingent on yosprala approval.
We seem to be gaining some momentum ahead of the PDUFA date. Nice to see some green numbers for a change. At most 4 more weeks before the FDA coughs up an answer.....
Comment by
2quick154 on Aug 11, 2016 8:41pm
Hopefully we can double from here with Yosprala approval... I don't see why not.